Research Funding

  • June 1, 2018 - May 31, 2023 - Novel radioimmunoconjugates for targeted alpha-particle therapy of metastatic prostatic cancer , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA223767
  • August 6, 2012 - July 31, 2019 - Internalizing human antibody-targeted nanosized siRNA therapeutics , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA171315
  • March 7, 2006 - March 31, 2016 - Mapping a clinically significant internalizing tumor epitope space , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA118919
  • March 1, 2010 - December 31, 2015 - Identifying antigens bound by novel scFvs targeting all subtypes of mesothelioma , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA129491

Education

Princeton University, B.A., June 1990, Molecular Biology and Biochemical Sciences University of California, San Francisco, Ph.D., Dec. 1994, Biochemistry and Biophysics

Honors & Awards

  • 1990
    Summa Cum Laude (Princeton University)
  • 1990
    Phi Beta Kappa (Princeton University)
  • 1990
    Sigma Xi (Princeton University)
  • 1990
    Sigma Xi Book Award (Princeton University)
  • 1990
    E.R. Squibb and Sons Thesis Prize (Princeton University)
  • 1990
    George Khoury '65 Prize For Academic Excellence (Princeton University)
  • 1990,1991
    Regents' Fellow (University of California at San Francisco)
  • 1994
    Chancellor's Fellow (University of California at San Francisco)
  • 1996-1999
    SmithKline Beecham Fellow of the Life Sciences Research Foundation
  • 1998
    Scleroderma Research Foundation investigator award
  • 2002
    American Cancer Society intramural research award
  • 2002
    BioSTAR/UC Discovery award
  • 2002
    CaPCure research award
  • 2002
    DOD New Investigator award
  • 2004
    MARF Investigator award
  • 2006
    MARF Investigator award
  • 2008
    AACR PanCan Pilot award
  • 2009
    UC Discovery SEED award
  • 2011
    MARF Investigator award

Selected Publications

  1. Su, Y., Zhang, X., Bidlingmaier, S., Behrens, C.R., Lee, N.K., and Liu, B. ALPPL2 is a highly specific and targetable tumor cell surface antigen. Cancer Res., 2020 Aug 31:canres.1418.2020.
    View on PubMed
  2. Sherbenou, D.W., Su, Y., Behrens, C.R., Aftab, B.T., Perez de Acha, O., Murnane, M., Bearrows, S.C., Hann, B.C., Wolf, J.L., Martin, T.G., and Liu, B. Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma. Clinical Cancer Res. 2020.
    View on PubMed
  3. He, J., Feng, J., Su, Y., Seo, Y., and Liu, B. Quantitative (99m)Tc Labeling Kit for HYNIC-Conjugated Single Chain Antibody Fragments Targeting Malignant Mesothelioma. Bioconjug Chem. 2020 Jul 6.
    View on PubMed
  4. Lee, N.K., Su, Y., Bidlingmaier, S., and Liu, B. Manipulation of cell-type selective antibody internalization by a guide-effector bispecific design. Mol Cancer Ther. 2019 Apr 8.
    View on PubMed
  5. Su, Y., Bidlingmaier, S., Lee, N.K., Liu, B. Combine Phage Antibody Display Library Selection on Patient Tissue Specimens with Laser Capture Microdissection to Identify Novel Human Antibodies Targeting Clinically Relevant Tumor Antigens. Methods Mol Biol. 2018; 1701:331-347.
    View on PubMed
  6. Lee, N.K., Bidlingmaier, S., Su, Y., Liu, B. Modular Construction of Large Non-Immune Human Antibody Phage-Display Libraries from Variable Heavy and Light Chain Gene Cassettes. Methods Mol Biol. 2018; 1701:61-82.
    View on PubMed
  7. Lee, N.K., Zhang, Y., Su, Y., Bidlingmaier, S., Sherbenou, D.W., Ha, K.D., Liu, B. Cell-type specific potent Wnt signaling blockade by bispecific antibody. Sci Rep. 2018 Jan 15;8(1):766.
    View on PubMed
  8. Su, Y., Liu, Y., Behrens, C.R., Bidlingmaier, S., Lee, N.K., Aggarwal, R., Sherbenou, D.W., Burlingame, A.L., Hann, B.C., Simko, J.P., Premasekharan, G., Paris, P.L., Shuman, M.A., Seo, Y., Small, E.J., and Liu, B. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight, 2018 Sept 6;3(17)e121497.
    View on PubMed
  9. Ha, K., Bidlingmaier, S., Su, Y., Lee, N.K., Liu, B. Identification of Novel Macropinocytosing Human Antibodies by Phage Display and High-Content Analysis. Methods Enzymol. 2017 585:91-110.
    View on PubMed
  10. Bidlingmaier, S., Ha, K., Lee, N.K., Su, Y., Liu, B. Proteome-wide identification of novel ceramide-binding proteins by yeast surface cDNA display and deep sequencing. Mol Cell Proteomics. 2016 Jan 4.
    View on PubMed
  11. Ha, K., Bidlingmaier, S., Su, Y., Lee, N.K., Liu, B. Macropinocytosis exploitation by cancers and cancer therapy. Frontier Physiology 2016 sept 12;7:381.
    View on PubMed
  12. Sherbenou, D.W., Aftab, B.T., Su, Y., Behrens, C.R., Wiita, A., Logan, A.C., Acosta-Alvear, D., Hann, B.C., Walter, P., Shuman, M.A., Wu, X., Atkinson, J.P., Wolf, J.L., Martin, T.G., Liu, B. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. J Clin Invest. 2016 Nov 14.
    View on PubMed
  13. Bidlingmaier, S., Su, Y., and Liu, B. Identification of Posttranslational Modification-Dependent Protein Interactions Using Yeast Surface Displayed Human Proteome Libraries. Methods Mol Biol, 2015;1319:193-202.
    View on PubMed
  14. Bidlingmaier, S. and Liu, B. Utilizing Yeast Surface Human Proteome Display Libraries to Identify Small Molecule-Protein Interactions. Methods Mol Biol, 2015;1319:203-14.
    View on PubMed
  15. Bidlingmaier, S., Liu, B. Combining phage and yeast cell surface antibody display to identify novel cell type-selective internalizing human monoclonal antibodies. Methods Mol Biol, 2015;1319:51-63.
    View on PubMed
  16. Bidlingmaier, S., Liu, B. Identification of novel protein-ligand interactions by exon microarray analysis of yeast surface displayed cDNA library selection outputs. Methods Mol Biol, 2015;1319:179-92.
    View on PubMed
  17. Ha, K.D., Bidlingmaier, S.M., Zhang, Y., Su, Y., and Liu, B. High-content analysis of antibody phage-display library selection outputs identifies tumor selective macropinocytosis-dependent rapidly internalizing antibodies. Mol Cell Proteomics. 2014 Aug22.
    View on PubMed
  18. Sherbenou, D.W., Behrens, C.R. Yang Su, Wolf, J.L., Martin III, T.G., and Liu, B. The Development of Potential Antibody-Based Therapies for Multiple Myeloma. Blood Rev., 2014 Sep 28.
    View on PubMed
  19. Behrens, R.C. and Liu, B. Methods for site-specific drug conjugation to antibodies. MAbs, 2013 Sept 27;(6)1: 46-53.
    View on PubMed
  20. McCabe, K.E., Liu B., Marks, J.D., Wu., H., and Wu, A. An engineered cysteine-modified diabody for PET imaging of ALCAM-positive pancreatic and colorectal tumor models. Molecular Imaging & Biology. 14(3):336-47 (2012).
    View on PubMed

Go to UCSF Profiles, powered by CTSI